Every 10-Q that Tvardi Therapeutics, Inc. (TVRD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TVRD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TVRD filings page.
Tvardi Therapeutics, Inc. is a clinical-stage biopharma developing oral STAT3 inhibitors TTI-101 (in Phase 1b/2 for hepatocellular carcinoma) and TTI-109 (next‑gen prodrug now through a positive Phase 1 healthy‑volunteer trial, with ulcerative colitis selected as its initial indication).
For the quarter ended June 30, 2026, Tvardi reported a net loss of $6.5 million and a six‑month net loss of $13.3 million, with no product revenue. Cash and cash equivalents were $15.8 million, total assets $17.5 million and accumulated deficit $123.7 million. Operating cash outflow for the first six months was $15.1 million.
Management states that these losses, limited cash and the need for significant additional funding raise substantial doubt about Tvardi’s ability to continue as a going concern. The company put in place a $200.0 million shelf registration and an at‑the‑market program, under which it has raised approximately $13.3 million gross through August 11, 2026.
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oral STAT3 inhibitors TTI-101 and TTI-109 for inflammatory and proliferative diseases. TTI-101 is in Phase 1b/2 for hepatocellular carcinoma, and TTI-109 is in a Phase 1 healthy volunteer trial.
For the three months ended March 31, 2026, Tvardi reported a net loss of $6.8 million, compared with $9.6 million a year earlier, driven by $4.9 million in research and development and $2.1 million in general and administrative expenses. The company had $19.9 million in cash and cash equivalents and $5.1 million in short-term investments, with an accumulated deficit of $117.3 million.
Management states that these resources are not sufficient to fund operations for at least one year and concludes that substantial doubt exists about Tvardi’s ability to continue as a going concern. On May 1, 2026, Tvardi filed a Form S-3 shelf registration for up to $200.0 million of securities, including an at-the-market facility of up to $12.5 million in common stock, which will only be available after SEC effectiveness.
Tvardi Therapeutics (TVRD) filed its Q3 2025 report, showing a net loss of $5.5 million for the quarter. Operating expenses were driven by research and development of $3.6 million and general and administrative of $2.3 million. Interest income was $0.4 million.
Liquidity remains a key focus. The company reported cash and cash equivalents of $21.4 million and short‑term investments of $15.0 million as of September 30, 2025. Cash used in operating activities was $17.8 million for the nine months. Management disclosed conditions that raise substantial doubt about the company’s ability to continue as a going concern.
Tvardi completed a reverse recapitalization with Cara Therapeutics on April 15, 2025, adding $24.992 million of cash and converting the company’s Convertible Notes into 1,265,757 shares, with a $7.8 million fair value gain recognized year‑to‑date. A subsequent event noted that the Phase 2 IPF study of TTI‑101 did not meet its goals on October 13, 2025. Common shares outstanding were 9,381,344 as of November 10, 2025.